With fresh funding round, the health tech pioneer continues to work toward managing the world's blood pressure.

LONDON, May 2, 2025 /PRNewswire/ -- Aktiia, a blood pressure intelligence platform, announces an oversubscribed $42 million (over CHF 34 million) Series B funding round, co-led by Earlybird Health and Wellington Partners, with new investors Kfund and naturalX Health Ventures, and participation from existing investors redalpine, Khosla Ventures, Molten Ventures, Translink Capital and Verve Ventures. The investment, which has brought the total financing to date above $100 million, will accelerate the company's mission to manage the world's blood pressure.

The latest investment builds on a period of significant momentum for the company during which it has achieved several major milestones, including securing CE marking for its innovative mobile phone camera blood pressure monitoring technology, securing regulatory approvals in Canada, Australia and Saudi Arabia, achieving 76% compounded annual revenue growth, and completing a pivotal clinical trial ahead of its U.S. FDA application submission. This Series B funding will fuel continued product innovation, expansion into new markets and the build out of its blood pressure intelligence platform to support enterprise use cases.

Alongside this funding, Aktiia is introducing its new brand identity: Hilo - a rebrand which reflects the company's global ambition to make cuffless, clinically validated blood pressure monitoring universally accessible and effortless. The transition to Hilo marks an important milestone in the company's journey, aligning with its vision of healthier blood pressure for all, while continuing to deliver the trusted technology and reports that have been central to its platform.

With more than 120,000 devices sold, Hilo has already established itself as a stand-out in the health tech space. The company has developed a foundation Machine Learning model specifically designed for blood pressure. The model has been trained on tens of billions of optical signals from real-world users and further refined with hundreds of millions of calibration points, strengthening its position as the leader in the emerging cuffless blood pressure monitoring (CBPM) category.

Raghav "Rags" Gupta, CEO of Hilo, commented:

"This funding round is a testament to the confidence our investors have in Hilo's groundbreaking technology and our mission to manage the world's blood pressure via more frequent, convenient and accurate measurements. With billions worldwide suffering from hypertension, only 20% of whom are in control of their blood pressure, the need for innovative, accessible blood pressure monitoring solutions has never been greater. Our rebrand to Hilo represents more than just a name change, it's a commitment to empowering users around the world with smarter tools to optimise their health. We are grateful to early Aktiia customers for their support and to our investors, new and existing, for their faith."

Christoph Massner, Principal at Earlybird Health, who will join Hilo's Board of Directors, commented:

"Hilo stands at the intersection of medical-grade precision and consumer-centric accessibility. By building on a validated medical device platform and an intuitive, user-friendly design, they bridge the gap between clinical reliability and everyday usability. It's a rare combination that empowers users to take meaningful control of their health with minimal effort. This is especially critical given the enormous medical need: uncontrolled high blood pressure remains one of the leading risk factors for death worldwide."

Johannes Fischer, Managing Partner at Wellington Partners, commented:

"We are excited to co-lead this financing and to be backing Hilo's innovative technology, which provides groundbreaking advancements to the billions of people with elevated blood pressure today. We believe that real-time and continuous access to blood pressure information will change the way we think about the monitoring and management of one of the most common risk factors to human health."

About Hilo

Aktiia, now trading under Hilo, was established in 2018 to transform how blood pressure is measured and therefore managed. By integrating advanced AI algorithms with extensive datasets, Hilo's cuffless blood pressure monitoring (CBPM) products offer convenient, valuable reports to give both individuals and healthcare professionals a useful picture of their blood pressure. The company's foundation model for blood pressure has been trained on billions of optical signals and hundreds of millions of readings across more than 120,000 users, underscoring its leadership in the CPBM category. The company's multidisciplinary team, composed of experts with extensive experience in biomedical signal processing, has contributed to over 120 peer-reviewed publications and holds more than 35 patents. Headquartered in Switzerland, Hilo continues to expand its global presence, transforming how blood pressure is understood and managed.

The Hilo system by itself is not intended to make diagnoses. Data should always be used in consultation with your healthcare provider.

Website: www.hilo.com

Photo -
Logo -

View original content:https://www.prnewswire.co.uk/news-releases/aktiia-secures-42-million-in-series-b-funding-round-and-rebrands-to-hilo-302444824.html

Images

Tags

More Like This

Aktiia Marks Record Year of Growth, Global Expansion and Scientific Progress

Hilo launches major app update, redefining the future of wearable health

Aktiia's Hilo Band Becomes First Cuffless Blood Pressure Monitor Cleared by FDA for Over-the-Counter Use

A Nation Under Pressure: New Hilo Report Reveals Stark Gaps in UK Blood Pressure Awareness, Behaviour and Monitoring

Sky Labs Launches their support of the American Heart Association's 'Established Investigator Award for Clinical Hypertension'

Global Healthcare Startup Sky Labs Attracts Investments Totaling KRW 20.7 Billion in a Series C Round

OMRON Healthcare Donates 4,000 Blood Pressure Monitors and Advances AFib Screening with AI-based Intellisense AFib Technology

Heart Failure start-up, Acorai, closes oversubscribed $4m funding round